Workflow
香雪制药:信披违法违规 董事长王永辉被罚1000万元

Core Viewpoint - Xiangxue Pharmaceutical (300147.SZ) is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws, resulting in an administrative penalty [1] Summary by Relevant Categories Company Penalties - The company has been ordered to rectify its actions and received a warning, along with a fine of 6 million yuan [1] - The actual controller and former chairman, Wang Yonghui, was fined 10 million yuan, which includes 3 million yuan as the directly responsible supervisor and 7 million yuan as the actual controller [1] - The former CFO, Lu Feng, received a warning and a fine of 2 million yuan [1] Other Executive Penalties - Former directors and executives Huang Bin and Xu Li were each warned and fined 1 million yuan [1] - Former CFO Chen Binghua was warned and fined 150,000 yuan [1]